Last reviewed · How we verify
Experimental: SNF472
SNF472 is a calcimimetic agent that binds to and activates the calcium-sensing receptor to reduce serum phosphate levels in patients with chronic kidney disease.
SNF472 is a calcimimetic agent that binds to and activates the calcium-sensing receptor to reduce serum phosphate levels in patients with chronic kidney disease. Used for Hyperphosphatemia in patients with chronic kidney disease on hemodialysis.
At a glance
| Generic name | Experimental: SNF472 |
|---|---|
| Sponsor | Sanifit Therapeutics S. A. |
| Drug class | Calcimimetic agent |
| Target | Calcium-sensing receptor (CaSR) |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
SNF472 works by allosterically activating the calcium-sensing receptor on the surface of cells, which leads to decreased secretion of parathyroid hormone and reduced serum phosphate concentrations. This mechanism is particularly relevant in hemodialysis patients where hyperphosphatemia is a significant clinical problem associated with cardiovascular complications and mortality.
Approved indications
- Hyperphosphatemia in patients with chronic kidney disease on hemodialysis
Common side effects
- Hypocalcemia
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: SNF472 CI brief — competitive landscape report
- Experimental: SNF472 updates RSS · CI watch RSS
- Sanifit Therapeutics S. A. portfolio CI